CC-223 is primarily investigated for its potential in cancer therapy, particularly targeting specific pathways involved in tumor growth and survival. It functions as an inhibitor of mTOR (mechanistic target of rapamycin), a key protein that regulates cell proliferation, metabolism, and angiogenesis. By blocking mTOR signaling, CC-223 aims to suppress the growth of cancer cells and inhibit tumor progression. Its application is being explored in various cancers, including solid tumors and hematologic malignancies, often in combination with other therapeutic agents to enhance efficacy. Clinical trials are ongoing to evaluate its safety, tolerability, and effectiveness in treating advanced or refractory cancers. Additionally, research is focused on identifying biomarkers to predict patient response and optimize treatment strategies.